{"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"groups":[{"description":"Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.","id":"BG000","title":"Ruxolitinib"},{"description":"Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting pre-specified requirements were given the opportunity to cross over to ruxolitinib treatment.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.82","value":"66.7"},{"groupId":"BG001","spread":"8.66","value":"68.7"},{"groupId":"BG002","spread":"8.78","value":"67.7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"141"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"153"},{"groupId":"BG002","value":"308"}],"units":"Participants"}],"title":"Female"},{"categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"167"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"153"},{"groupId":"BG002","value":"308"}],"units":"Participants"}],"title":"Male"}],"paramType":"NUMBER","populationDescription":"Gender data for one patient in the placebo arm was not available because of loss of study data during a move to a new location by the clinical site.","title":"Sex/Gender, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"139"},{"groupId":"BG002","value":"277"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Other"}],"description":"Race data for one patient in the placebo arm was not available because of loss of study data during a move to a new location by the clinical site.","paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"154"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Primary myelofibrosis"},{"categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"97"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Post-polycythemia vera-myelofibrosis"},{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"57"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Post-essential thrombocythemia-myelofibrosis"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Missing"}],"paramType":"NUMBER","title":"Disease Subtype","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1247.0","value":"2745.7"},{"groupId":"BG001","spread":"1388.5","value":"2797.6"},{"groupId":"BG002","spread":"1317.3","value":"2771.5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}]}],"description":"Spleen volume was measured by magnetic resonance imaging or computed tomography scans. Data for one patient in the placebo arm was not available because of loss of study data during a move by the clinical site.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Spleen volume","unitOfMeasure":"cm˄3"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"236"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"67"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Negative"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"309"}],"units":"Participants"}],"title":"Unknown/Missing"}],"description":"JAK2V617F is a mutation in the pseudokinase domain of Janus Kinase 2 (JAK2) (at amino acid 617, valine to phenylalanine) that results in constitutive activation of JAK2. Mutation status was determined using a validated assay on bone marrow as well as peripheral blood.","paramType":"NUMBER","title":"JAK2 V617F Mutation Status","unitOfMeasure":"participants"}]}